Trials / Completed
CompletedNCT00620854
A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Tarsa Therapeutics, Inc. · Industry
- Sex
- Female
- Age
- 45 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This study compares the performance of different doses of oral recombinant salmon calcitonin (rsCT).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Recombinant Salmon Calcitonin (rsCT) | Single dose of a nasal spray or one of two doses of tablets, randomized to visits 2, 3, and 4. |
| DRUG | Oral Tablet | 0.15 mgs recombinant salmon calcitonin, single oral dose |
| DRUG | Oral Tablet | 0.2mgs recombinant salmon calcitonin, single oral tablet |
| DRUG | Nasal Spray | 200 IU recombinant salmon calcitonin, single intranasal spray |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2008-04-01
- Completion
- 2008-04-01
- First posted
- 2008-02-22
- Last updated
- 2012-02-01
- Results posted
- 2009-09-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00620854. Inclusion in this directory is not an endorsement.